Butcher's Broom

What is Butcher's Broom?

Butcher's broom is the rhizome and root of Ruscus aculeatus L., an evergreen shrub in the Asparagaceae, the same family as garden asparagus. The stiff green structures that look like leaves are cladodes, flattened stems with a sharp terminal spine, which is where the aculeatus in the name comes from and why European butchers once bundled the plant to scour cutting blocks. The medicinal material is underground, and the European Pharmacopoeia sets its standard at not less than 1.0 percent total sapogenins expressed as ruscogenins, measured after acid hydrolysis of the steroidal saponins.

Common Names

• Butcher's broom, box holly, knee holly, sweet broom, pettigree

• Rusci rhizoma, Rusci aculeati rhizoma (pharmacopoeial names)

• Petit houx (French), Mäusedorn (German)

Primary Active Compounds

• Ruscogenin, the principal steroidal sapogenin, in the underground parts at roughly 0.12 percent as the free aglycone

• Neoruscogenin, the second sapogenin, differing by a single double bond

• Spirostanol and furostanol glycosides carrying those aglycones: ruscin, ruscoside, deglucoruscin, deglucoruscoside, 22-O-methyl-deglucoruscoside and 1-O-sulpho-ruscogenin

• Esculin, a coumarin isolated from Rusci rhizoma for the first time by Barbič and colleagues in Phytochemistry in 2013, volume 90, pages 106 to 113

• Sitosterol, campesterol, stigmasterol, and tyramine

Key Note

Butcher's broom is not a nutrient and has no metabolic role in humans. It is a pharmacologically active plant with a defined mechanism, alpha-adrenergic venoconstriction, and clinical trial data unusually good for the supplement aisle. The catch is what those trials tested.

Almost everything published about it in the last fifty years traces back to a single French pharmaceutical product and a single extract whose specification was never published.

Primary Functions & Benefits

Butcher's broom is sold for one cluster of problems: symptoms of chronic venous disease in the legs, and the related problem of hemorrhoids.

• Venoconstriction and reduced venous capacity. Ruscus extract contracts veins through alpha-1 and alpha-2 adrenergic receptors, shown by Rubanyi, Marcelon and Vanhoutte in canine saphenous vein rings in General Pharmacology in 1984, volume 15, pages 431 to 434. Boyle's 2003 meta-analysis measured a 0.70 mL per 100 mL reduction in venous capacity against placebo, standard error 0.19.

• Reduced capillary permeability and lymphatic tone. Bouskela, Cyrino and Marcelon showed in the Journal of Cardiovascular Pharmacology in 1993, volume 22, pages 225 to 230, that intravenous Ruscus extract and intravenous hesperidin methyl chalcone both cut leakage sites induced by bradykinin, histamine and leukotriene B4. Monjotin and Tenca reported contractile effects on human lymphatic smooth muscle cells in Microvascular Research in 2022, volume 139, article 104274.

• Anti-elastase activity. Facino and colleagues reported in Archiv der Pharmazie in 1995, volume 328, pages 720 to 724, that ruscogenins competitively inhibit elastase at IC50 119.9 micromolar with no effect on hyaluronidase.

• Hemorrhoid symptom relief. The second registered indication for Cyclo 3 Fort, at four to five capsules daily, on far thinner evidence than the leg indication; the oldest cited work is a 1977 German proctology report by Salzmann, Ehresmann and Adler in Fortschritte der Medizin, volume 95, pages 1419 to 1422.

Forms & Standardization

This is where the gap between what was tested and what is sold becomes measurable.

The tested extract

Cyclo 3 Fort declares "dry Ruscus aculeatus extract, titrated in sterolic heterosides, 150 mg," and publishes no drug-to-extract ratio, solvent or ruscogenin percentage. The EMA assessor reviewing the file noted that in most published studies the extract came from Pierre Fabre Médicament and that no author gives any precision on it. The most-cited botanical preparation in venous phytotherapy has an undisclosed specification.

European monograph preparations

The EU herbal monograph on Ruscus aculeatus L., rhizoma (EMA/HMPC/188804/2017, adopted 20 November 2018) recognizes powdered herbal substance at 350 mg three times daily; aqueous dry extract, DER 2.5 to 6.5:1, at 150 to 200 mg per dose to a maximum of 450 mg daily; dry extract, DER 5.0 to 8.5:1 in 80 percent ethanol, at 86 mg once or twice daily; and dry extract, DER 6 to 9:1 in 96 percent ethanol, at 45 mg twice daily. The German monograph and ESCOP both land on 7 to 11 mg of total ruscogenins daily, and the arithmetic agrees: 1,050 mg of powdered rhizome at the Pharmacopoeia minimum is about 10.5 mg.

What "10 percent ruscogenins" on a US label means

Usually nothing verifiable. Free ruscogenin in the rhizome runs around 0.12 percent while total sapogenins after acid hydrolysis run at or above 1.0 percent, so the same claim means a tenfold concentration step against one figure and eighty-fold against the other. No US label reviewed here says which method was used.

What US shelves actually carry

Querying the NIH Dietary Supplement Label Database API version 9.4.0 on 4 September 2026, filtering on the ingredient group "Butcher's Broom" across all market statuses, returned 166 labels from 59 brands, 92 of them currently on market. Of those 166:

• 23 are single-ingredient butcher's broom products, 15 of them on market. The other 143, 86 percent, are blends.

• 66 labels, 40 percent, pair it with horse chestnut. Thirty-six contain vitamin C.

• 78 place it inside a proprietary blend, and 80 of the 166 give no numeric milligram figure for it anywhere on the Supplement Facts panel. Among the 86 that do, the median declared amount per daily serving is 150 mg, range 10.6 mg to 1,000 mg.

• Only 14 labels use the word "ruscogenin" anywhere, only 12 attach a number to it, and only seven of those are on market. That is 7.2 percent standardized to the marker compound in any form.

• Five labels contain hesperidin methyl chalcone. None reproduces the tested combination.

The twelve exceptions run from HoltraCeuticals Vein Aid Rx and Vinco's Vein Support (200 mg at 9 to 11 percent ruscogenins) through Swanson Superior Herbs and Douglas Laboratories Butcher's Broom Max-V at 150 mg, Karuna Venous Support at 110 mg declared as 11 mg of ruscogenins, LifeSeasons Women's Vitali-T and Natural Factors VeinSense near 100 mg, and ProCaps Circulation & Vein Support at 80 mg, down to Douglas Laboratories Varitonin and Martin Avenue Pharmacy Vascular Health Support at 50 mg.

The closest thing to the tested product

Varitonin is the nearest match on US shelves, and it is not close. Per capsule it carries 50 mg of butcher's broom at 8 percent saponins calculated as ruscogenins, 125 mg of hesperidin methyl chalcone and 250 mg of vitamin C, plus 250 mg of horse chestnut and 60 mg of gotu kola that were never in the trials, at one capsule once or twice daily. Against the tested 300 to 450 mg of Ruscus extract per day that is one sixth to one ninth of the exposure, inside a five-ingredient formula.

The bare-powder majority

The best-selling single-ingredient products are unstandardized ground rhizome: Nature's Way at 470 mg capsules twice daily, Nature's Answer at 1,000 mg per serving, and Swanson, Vitamin World, Puritan's Pride and Solaray at 440 to 470 mg. None declares a sapogenin content, and none is the material any trial used.

Food Sources

Butcher's broom is not a food ingredient in any meaningful sense, but it is not entirely inedible either.

• The young spring shoots are eaten in Italy, Greece and Turkey like thin wild asparagus. They come from the aerial parts, where ruscogenin runs around 0.08 percent against 0.12 percent in the rhizome, and a plate of them is a few dozen grams of tissue that is mostly water.

• Reaching about 10 mg of total ruscogenins needs roughly 1 gram of dried rhizome at the Pharmacopoeia minimum of 1.0 percent total sapogenins, or about 8.3 grams measured as free aglycone. Nobody eats the rhizome; it is woody and bitter.

• Vitamin C, the third tested ingredient, is trivially dietary: a medium orange supplies roughly 70 mg, so 200 to 300 mg daily is three to four oranges. Hesperidin, the parent of the second tested ingredient, is dietary too at roughly 40 to 60 mg of flavanones per orange. Hesperidin methyl chalcone is not dietary at all.

Food is irrelevant for the botanical, adequate for the vitamin C and impossible for the modified flavonoid.

Who Should Take Butcher's Broom

The population with any evidence behind it is narrow.

• Adults with symptomatic chronic venous disease, CEAP clinical classes C0s through C4: leg heaviness, aching, cramps, tingling and ankle swelling with or without visible varicose veins. Vanscheidt 2002 enrolled Widmer grade I and II, CEAP C3 to C4.

• Adults whose main complaint is the symptom cluster rather than the visible veins. Across both meta-analyses the largest effects are on heaviness and paresthesia, not on limb appearance.

• People already using compression who want an adjunct. The ESVS 2022 guidelines put venoactive drugs at Class IIa, Level A, which is "should be considered" rather than "is recommended."

• Adults with acute hemorrhoid symptoms, on the understanding that the registered European use is short-course only.

Butcher's broom has never been shown to close a varicose vein, prevent progression, or heal a venous leg ulcer. The Cochrane phlebotonics review found low-certainty evidence that the drug class does not influence ulcer healing, risk ratio 0.94, 95 percent confidence interval 0.79 to 1.13, six studies, 461 participants.

Who Should AVOID or Use Caution

Contraindications

• Known hypersensitivity to Ruscus aculeatus, the only formal contraindication in the EU monograph.

• Children and adolescents under 18, because no data exist below that age.

• Pregnancy and breastfeeding. Safety has not been established, and the Cyclo 3 Fort label states that a risk to the newborn or infant cannot be excluded.

Use Caution

• People with diabetes. A case in the Journal of Emergency Medicine describes a 39-year-old woman who developed diabetic ketoacidosis five days after starting butcher's broom for ankle swelling, requiring intravenous fluid, insulin and calcium gluconate. It is the only reported serious metabolic event.

• Anyone taking a drug that acts on alpha-adrenergic receptors. The EMA assessment states that because Ruscus extract contains substances with alpha-adrenergic stimulating properties, pharmacodynamic interactions with drugs that potentiate or antagonize that signaling are plausible, while noting no case reports were found.

• People with G6PD deficiency taking the combination product, a risk from the ascorbic acid rather than the botanical, and anyone with a history of microscopic colitis or unexplained chronic diarrhea.

• People who bruise or bleed easily are routinely warned off this plant on general herbal principles, though no coagulation data supports that warning.

Critical Safety Point

Diarrhea is a common, labeled adverse reaction of the tested product, and the French summary of product characteristics instructs prescribers to stop treatment if it develops. Reversible microscopic colitis, predominantly lymphocytic, appears in the spontaneous reporting section of the same label, backed by case series in Gastroentérologie Clinique et Biologique in 1993, 1996 and 2000. New persistent watery diarrhea here is a reason to stop and get a colonoscopy, not to push through.

Recommended Dosages

Powdered rhizome and dry extracts, European monograph

Powdered rhizome, 350 mg three times daily. Aqueous extract, DER 2.5 to 6.5:1, 150 to 200 mg per dose to a maximum of 450 mg daily. Ethanolic extract at DER 5.0 to 8.5:1, 86 mg once or twice daily; at DER 6 to 9:1, 45 mg twice daily.

Standardized ruscogenins

7 to 11 mg of total ruscogenins daily, the figure carried by the German monograph and by ESCOP. Almost no US product lets you calculate this.

The tested fixed combination

Cyclo 3 Fort, per capsule: 150 mg Ruscus dry extract, 150 mg hesperidin methyl chalcone, 100 mg ascorbic acid. For veno-lymphatic insufficiency the label dose is two to three capsules daily, giving 300 to 450 mg each of Ruscus extract and hesperidin methyl chalcone plus 200 to 300 mg of ascorbic acid. For hemorrhoid symptoms it is four to five capsules daily, giving 600 to 750 mg of each of the first two and 400 to 500 mg of vitamin C.

Duration

The EU monograph tells users to consult a clinician if symptoms persist beyond two weeks. Trial durations run 28 days (Allaert 2011), eight weeks (Aguilar Peralta 2007), 12 weeks (Vanscheidt 2002, Guex 2009) and 90 days (Beltramino 2000). No controlled trial has run beyond three months, so nothing is known about a year of continuous use.

Timing & Administration

• Take with water. The Cyclo 3 Fort label specifies oral administration with water and does not require food. Nature's Way, the largest single-ingredient US brand in the label database, directs two capsules daily preferably with food; a bitter saponin-rich powder on an empty stomach is a common cause of nausea.

• Split the dose. Both the monograph posology (350 mg three times daily) and the tested regimen (two to three capsules daily) are divided. There is no evidence for once-daily dosing of the powdered herb.

• Heat matters more here than for most botanicals. Warming augments the venoconstrictor response and cooling suppresses it, documented in dog vein at 24, 37 and 41 degrees Celsius and in hamster microvasculature at 25, 36.5 and 40 degrees. That lines up with the complaint that heavy legs are worse in summer.

Timeline of Effects

• Days 1 to 14. Aguilar Peralta's open study of 124 patients on two Cyclo 3 Fort capsules daily for eight weeks reported the sharpest drop within two weeks: intense pain fell from 79 percent of patients to 20 percent, heaviness from 85 to 12 percent, cramps from 74 to 8 percent and edema from 82 to 14 percent. There was no placebo arm, so expect a large expectation effect inside those numbers.

• Week 4. Allaert's 2011 open trial in 65 women with CEAP C2s and C3s measured venous refilling time by mercury strain-gauge plethysmography at day 0 and day 28: 11.7 plus or minus 4 seconds rising to 13.8 plus or minus 4.4 seconds, a 26 percent change.

• Weeks 8 to 12. Vanscheidt's placebo-controlled trial measured leg volume falling 16.5 mL at eight weeks and 20.5 mL at 12 weeks against placebo, an area-under-baseline difference of 827 mL times day. Every placebo-controlled result in this literature that reached significance on an objective measure needed at least eight weeks.

• When to conclude it is not working. If leg heaviness and evening ankle swelling have not measurably improved after 12 weeks at a dose that actually delivers 7 to 11 mg of ruscogenins daily, stop.

Benefits of Taking Butcher's Broom

Symptom reduction in chronic venous disease, moderate to good evidence

Kakkos and Allaert's 2017 meta-analysis of 10 randomized double-blind placebo-controlled trials in 719 patients reported risk ratios against placebo of 0.35 for leg pain (number needed to treat 5), 0.26 for heaviness (NNT 2.4), 0.53 for feeling of swelling (NNT 4), 0.27 for paresthesia (NNT 1.8) and 0.54 for global symptoms (NNT 4.3).

Objective edema measures, smaller and less consistent

The same meta-analysis found standardized mean differences of minus 0.74 for ankle circumference (95 percent CI minus 1.01 to minus 0.47) and minus 0.61 for leg or foot volume. Boyle's earlier, larger pool found the edema score, calf circumference and ankle circumference changes all nonsignificant, at minus 0.43 points, minus 0.73 cm and minus 1.17 cm. Two meta-analyses of overlapping literature disagreed on whether the swelling effect is real.

Head-to-head against other venoactive drugs

Allaert's 2012 meta-analysis of 10 publications between 1975 and 2009 covering 1,010 patients ranked mean ankle circumference reduction as micronized purified flavonoid fraction minus 0.80 cm, Ruscus extract minus 0.58 cm, hydroxyethylrutoside minus 0.58 cm, plain diosmin minus 0.20 cm and placebo minus 0.11 cm.

Quality of life, weak

Guex's QUALITY study followed 917 Mexican patients for 12 weeks and reported improvement on SF-12 and CIVIQ, but was observational with no control group. Cochrane found moderate-certainty evidence of little or no quality-of-life difference for the wider phlebotonic class, standardized mean difference minus 0.06, five studies, 1,639 participants.

Guideline position

The 2018 international guidelines assigned Grade A evidence to the Ruscus, hesperidin methyl chalcone and vitamin C combination for pain, heaviness, feeling of swelling, paresthesia and ankle circumference. Read the subject of that sentence carefully.

Potential Negatives & Side Effects

The frequencies below come from the tested product's regulatory label, the only place a full categorized list exists for this plant.

Common

• Diarrhea, which the label notes may be severe, and abdominal pain

Uncommon

• Dyspepsia, nausea, erythema, pruritus, insomnia, muscle spasms

Rare

• Vertigo, nervousness, vein pain, aphthous stomatitis, elevated alanine aminotransferase

Spontaneously reported, no frequency established

• Reversible microscopic colitis, essentially lymphocytic

• Maculopapular erythema and urticaria

The colitis signal has a published trail. Ouyahya and colleagues reported Cyclo 3 Fort diarrhea with lymphocytic colitis in Gastroentérologie Clinique et Biologique in 1993, volume 17, pages 65 to 66; Thomas-Antérion and colleagues reported four cases of unexplained chronic diarrhea on the same product in the Revue de Médecine Interne in 1993, volume 14, pages 215 to 217; Pierrugues and Saingra added four more colitis cases in 1996, volume 20, pages 916 to 917; and Dharancy and colleagues described one with ileal villous atrophy in 2000, volume 24, pages 134 to 135. In every series the colitis resolved after the drug was stopped.

Contact and systemic dermatitis are documented too. In the Vanscheidt placebo-controlled trial, 48 adverse events occurred across both arms, 22 in the Ruscus group, and only one was judged related to study medication at the "unlikely" grade. Single-ingredient butcher's broom at monograph doses appears well tolerated over 12 weeks.

Deficiency Symptoms

Butcher's broom is not an essential nutrient, has no recommended intake, and no deficiency state exists or can exist. Nobody has ever been ruscogenin-deficient.

What butcher's broom addresses

A mechanical and inflammatory problem. In chronic venous disease, valve incompetence lets blood pool in the leg veins under standing pressure, and that venous hypertension distends postcapillary venules, widens interendothelial gaps and drives fluid and macromolecules into the interstitium. Butcher's broom is proposed to work against the pressure component and the leakage component at once. It does not repair a valve.

Bottom line

There is no baseline requirement to meet, no blood test to run and no population at risk of lacking it. Anyone framing butcher's broom as correcting a shortfall is describing a mechanism the plant does not have.

Toxicity Symptoms

At high intake

No human overdose has been reported for the tested combination product; its label says so explicitly. The concerns at supratherapeutic intake are extensions of the known effects rather than novel toxicities: worsening diarrhea and abdominal pain from the saponin fraction, and, in G6PD deficiency, hemolytic anemia from a large ascorbic acid load. No acute lethal dose is established in humans.

Signs to reduce or stop

• Watery diarrhea persisting more than a couple of days, especially if nocturnal. Get evaluated for microscopic colitis rather than switching brands.

• New abdominal cramping with weight loss, or rash, urticaria, spreading eczematous eruption or mouth ulcers

• Abnormal liver enzymes on routine bloodwork, given the rare ALT signal

General note

The larger unknown is not overdose. It is that no genotoxicity, reproductive toxicity or carcinogenicity studies have been performed on Ruscus aculeatus preparations. The EMA assessment flags this and notes that radiolabeled distribution work showed deep penetration of radioactivity into bone marrow after both intravenous and oral dosing, which the assessor said points to a need for genotoxicity testing. It was never done, because a traditional-use registration does not require it. That is a gap in the file rather than a finding of harm, and one reason the monograph caps self-treatment at two weeks.

How Butcher's Broom Works

The mechanism is better characterized than for most botanicals on the shelf, and it is unusual.

Direct alpha-adrenergic agonism on the venous wall

The steroidal saponins act as agonists at postjunctional alpha-1 and alpha-2 adrenergic receptors on venous smooth muscle, producing contraction without the arterial effects a systemic adrenergic agonist would cause. Bouskela's 1994 work in the Journal of Cardiovascular Pharmacology, volume 24, pages 165 to 170, pinned it down: venular constriction in the hamster cheek pouch was abolished by prazosin and by the calcium blocker diltiazem at 10 to the minus 9 molar, and by the alpha-2 antagonist rauwolscine only above 10 to the minus 6 molar. The alpha-1 component dominates and the response is calcium-dependent.

Selective for venules, not arterioles

Intravenous Ruscus extract at 5 mg/kg constricted venules in the same preparation while leaving arteriolar diameter and mean arterial pressure unchanged. A drug that constricted arterioles would raise blood pressure.

Temperature amplifies rather than blunts the effect

Rubanyi's canine saphenous vein experiments at 24, 37 and 41 degrees Celsius found that cooling inhibited the Ruscus response while warming augmented it, the opposite of what happens with sympathetic nerve stimulation. Whatever else this plant is doing, it is not simply mimicking norepinephrine.

The receptor population differs in diseased veins

Miller, Rud and Gloviczki at the Mayo Clinic tested human greater saphenous veins and varicose tributaries in organ chambers, in International Angiology in 2000, volume 19, pages 176 to 183. Contractions to norepinephrine were larger in control veins, but contractions to Ruscus extract were larger in the varicose tributaries, and alpha blockade reduced the Ruscus response only in the varicose veins.

Permeability reduction at the postcapillary venule

Barbič's 2013 isolation work tested individual constituents against thrombin-induced hyperpermeability in human microvascular endothelial cells. At 10 micromolar, deglucoruscin cut hyperpermeability to 41.9 percent of control, ruscin to 42.6 percent and esculin to 53.3 percent, while the free aglycone neoruscogenin managed only 71.8 percent at 100 micromolar. At 100 micromolar the saponins reversed direction and increased the thrombin effect, a biphasic response that argues against the assumption that more is better.

The other two ingredients contribute independently

Hesperidin methyl chalcone inhibited bradykinin-, histamine- and leukotriene B4-induced leakage in its own right in Bouskela 1993. Ascorbic acid is a cofactor for prolyl and lysyl hydroxylase in collagen synthesis. Three ingredients, three plausible mechanisms, tested only together.

Synergistic Supplements

• Hesperidin methyl chalcone. The only synergy claim with trial data behind it, and that data is on the fixed combination rather than the pairing alone. Note the chemistry precisely: hesperidin is C28H34O15, molecular weight 610.56, a flavanone glycoside from citrus. Hesperidin methyl chalcone is C29H36O15, molecular weight 624.59, CAS 24292-52-2, hesperidin with the flavanone C-ring opened to a chalcone and a methyl group added, a semisynthetic derivative made for water solubility and stability. It is not hesperidin, it is not found in oranges, and a hesperidin capsule is not a substitute. The NutrientWise archive covers hesperidin itself separately.

• Ascorbic acid. The third component at 100 mg per capsule, 200 to 300 mg at the tested daily dose.

• Horse chestnut seed extract. The most common shelf pairing in the US, on 66 of the 166 labels. There is a mechanistic argument for it, since ruscogenins inhibit elastase and escin inhibits hyaluronidase, two different perivascular matrix enzymes. There is no trial of the combination.

• Graduated compression stockings. The only intervention here with better evidence than any oral agent, and the guidelines treat drugs as adjunctive to it rather than as replacements.

Interactions & What NOT to Take

• Alpha-adrenergic antagonists. Doxazosin, terazosin, prazosin, tamsulosin, alfuzosin and silodosin all block the receptor butcher's broom is proposed to stimulate, and prazosin abolished the Ruscus response at nanomolar concentrations in animal tissue. No clinical report exists, but the pharmacology is direct and the EMA calls the interaction plausible.

• Alpha-adrenergic agonists. Midodrine, phenylephrine and pseudoephedrine act on the same receptor in the same direction. Redman's 2000 review in the Journal of Alternative and Complementary Medicine proposed Ruscus aculeatus for orthostatic hypotension precisely because it is an alpha agonist that does not cause supine hypertension. That is an argument for effect and a warning about stacking.

• Monoamine oxidase inhibitors. Phenelzine, tranylcypromine, isocarboxazid and selegiline, on the tyramine content rather than the saponins. No case has been published.

• Antihypertensives generally. A venoconstrictor is a poor thing to add blindly to a regimen being titrated for blood pressure.

• Ascorbic acid and laboratory tests. The Cyclo 3 Fort label warns that the vitamin C component can interfere with test results, including glucose and occult blood assays. Anticoagulant and antiplatelet cautions are widely listed with no pharmacokinetic study behind them; treat those as untested rather than established.

• What NOT to take alongside it. Another venoactive product. Stacking butcher's broom with a diosmin-hesperidin product and a horse chestnut product means three overlapping mechanisms, three sets of gastrointestinal side effects and no way to tell which is doing anything.

Quality, Testing & Adulteration

Species substitution

Ruscus hypoglossum, Ruscus hypophyllum, Ruscus hyrcanus and Ruscus ponticus all appear in the phytochemical literature with similar saponin chemistry, and Ruscus ponticus preparations have been studied pharmacologically in Georgia. Molecular authentication using trnH-psbA barcoding plus HPLC-PDA exists because morphological identification of dried rhizome is unreliable. A US label saying only "butcher's broom root" does not establish which Ruscus is in the bottle.

No US pharmacopoeial standard in general use

The only assay standard is the European Pharmacopoeia requirement of not less than 1.0 percent total sapogenins expressed as ruscogenins. In the 166-label database pull, exactly zero products cited a pharmacopoeial specification of any kind.

Wild collection and a protected species

Ruscus aculeatus is listed under Annex V of the EU Habitats Directive and protected in several European countries, restricting wild harvest of the material the trials used. It is also slow to propagate; University of Barcelona researchers published work in Plant Physiology and Biochemistry in 2019, volume 141, pages 133 to 141, on producing ruscogenins in cell and root-rhizome cultures because the plant is threatened and recalcitrant in vitro. Supply pressure on a slow-growing protected rhizome is a structural incentive for substitution.

What belongs on a certificate of analysis

• Botanical identity confirmed to species, ideally by DNA barcoding, with the plant part stated as rhizome and root, and absence of other Ruscus species

• Total sapogenins expressed as ruscogenins by HPLC, with the method stated and, critically, whether the assay ran before or after acid hydrolysis

• Drug-to-extract ratio and extraction solvent, plus heavy metals, microbial limits and residual solvents

What a buyer can verify

Almost nothing from the panel alone. Forty-eight percent of the labels give no milligram figure for butcher's broom because it sits inside a proprietary blend, and 93 percent give no ruscogenin number. Anyone who wants the tested exposure has to ask the brand for a certificate of analysis and, in this category, will usually be sent a specification sheet rather than a lot-specific result.

Special Considerations

• The regulatory split is the story. The EMA granted Ruscus aculeatus rhizome traditional use registration only, not well-established use, on 20 November 2018. The assessor's stated reason is exact: studies conducted with the combination of Ruscus extract and hesperidin methyl chalcone were not taken into consideration, and only one clinical study using Ruscus extract alone was found. Europe's regulator looked at the evidence base everyone cites and concluded that, for the plant by itself, it amounts to tradition.

• That one study is Vanscheidt 2002. Multicenter, double-blind, randomized, placebo-controlled, 10 centers, 166 women randomized, 148 analyzed, 12 weeks, using Fagorutin Ruscus Kapseln at the German monograph dose. It is a good trial. It is one trial.

• The Cochrane review does not cover it. Martinez-Zapata and colleagues, Cochrane Database of Systematic Reviews, 3 November 2020, article CD003229, fourth version, searched to 12 November 2019, included 69 randomized trials of oral phlebotonics, of which 56 with 7,690 participants provided quantifiable data: 28 on rutosides, 11 on hidrosmine and diosmine, 10 on calcium dobesilate, two each on Centella asiatica, aminaftone and French maritime pine bark, and one on grape seed extract. That accounts for all 56. Ruscus is not among the drugs named in the selection criteria and contributed no trials.

• Funding and authorship concentration. Allaert, affiliated with Cen Biotech in Dijon, is an author on the 2011 plethysmography study, the 2012 ankle-edema meta-analysis, the 2016 review and the 2017 meta-analysis with Kakkos. The 2017 symposium that proposed Grade 1A was titled "New Data on Chronic Venous Disease: A New Place for Cyclo 3 Fort," held at the European Venous Forum in Porto on 30 June 2017. None of this makes the findings wrong. It does mean the evidence base was substantially built by parties with an interest in one branded product.

• Not the Rutin situation. In the Rutin issue the trials used a different molecule from the one on the label. Here the molecule is right; Ruscus extract really is Ruscus extract in both the trial and the capsule. The problem is that it never traveled alone, and no factorial design was run to break the three-ingredient signal apart.

• A second combination exists. Cappelli, Nicora and Di Perri tested RAES in Drugs Under Experimental and Clinical Research in 1988, volume 14, pages 277 to 283: Ruscus extract 16.5 mg plus plain hesperidin 75 mg plus ascorbic acid 50 mg, three times daily in 40 crossover patients. Different dose, different flavonoid, same literature stream.

Research Status & Evidence Quality

Strong Evidence For

• Reduction of subjective leg symptoms in chronic venous disease, from the tested three-ingredient combination, numbers needed to treat 1.8 to 5 (Kakkos and Allaert 2017, 10 trials, 719 patients).

• Direct venoconstriction through alpha-1 and alpha-2 adrenergic receptors, in canine saphenous vein, hamster cheek pouch microvasculature and human varicose vein tissue.

Moderate Evidence For

• Reduction of ankle circumference and leg or foot volume, where Kakkos 2017 and Boyle 2003 disagree and Vanscheidt 2002 found a 20.5 mL leg volume difference at 12 weeks with the mono-preparation.

• Reduced microvascular permeability, well shown in animal and cell models, inferred rather than measured in humans.

Emerging / Preliminary Evidence For

• Lymphatic contractility, from 2022 human lymphatic smooth muscle cell work by the manufacturer's research institute.

• Orthostatic hypotension, proposed in a 2000 review with a single case report and never tested in a controlled trial.

• Capillaroscopic morphology changes, from one open-label study of 124 patients with no control arm, and hemorrhoids, a registered European indication resting largely on pre-1980 reports.

Research Limitations

• Essentially all of the trials generating the Grade A recommendation used a fixed three-ingredient combination, and no factorial study exists, so the contribution of butcher's broom alone cannot be estimated. That is why the EMA downgraded the plant to traditional use.

• The tested extract has no published drug-to-extract ratio, solvent or marker specification, so an independent manufacturer cannot reproduce it even in principle.

• No trial has exceeded 90 days, in a lifelong condition treated indefinitely, and no genotoxicity, carcinogenicity or reproductive toxicity studies have been performed.

• The comparison patients most need, botanical versus graduated compression, has not been run.

• Two meta-analyses of overlapping trials disagreed about whether the objective edema effect is real, and the more favorable one carries authorship links to the manufacturer.

• The independent Cochrane review of phlebotonics did not include Ruscus among the drugs it assessed.

Summary & Key Takeaways

Butcher's broom is the rare supplement whose evidence is better than its category and worse than its marketing implies, for reasons that have nothing to do with the plant and everything to do with what else was in the capsule. The venoconstrictor mechanism is genuine and specific: alpha-1 and alpha-2 adrenergic agonism on venular smooth muscle, calcium-dependent, augmented by warmth, sparing arterioles. That is why European regulators have taken this plant seriously for fifty years. What the trials tested was 150 mg of an unspecified Ruscus extract bundled with 150 mg of hesperidin methyl chalcone and 100 mg of ascorbic acid, two to three times a day. Of 166 American labels carrying butcher's broom, five contain hesperidin methyl chalcone and not one matches that formula at that dose.

Bottom Line

If your reason for buying butcher's broom is the clinical trial evidence, you cannot buy the tested product in the United States, and no study has isolated how much of the benefit belongs to the Ruscus fraction. The closest approximation is a product declaring total ruscogenins in milligrams, dosed to reach 7 to 11 mg daily, taken for a full 12 weeks, alongside compression rather than instead of it. Only 12 of 166 labels give you the number needed for that arithmetic.

Key Safety Points

• Diarrhea is a common labeled reaction of the tested product and the instruction on that label is to stop, not to persist

• Reversible lymphocytic colitis appears in at least four French case reports and series published between 1993 and 2000

• One case of diabetic ketoacidosis was reported five days after a 39-year-old woman with diabetes started butcher's broom

• Alpha-blockers, alpha-agonists and MAO inhibitors are the pharmacologically coherent interaction concerns

• Not for use under 18, in pregnancy or while breastfeeding, and no genotoxicity or carcinogenicity testing has ever been performed on this plant

• Self-treatment beyond two weeks without a clinical assessment is outside the European monograph

Special Note

The lesson here runs opposite to the usual complaint about supplement research. The usual problem is evidence too thin to support the product. Here the evidence is respectable and the product is missing. When a meta-analysis pools ten thousand subjects on a fixed combination and nobody runs the arm that separates the ingredients, the combination is what was proven. Before you accept a botanical's trial record, find out how many other things were in the capsule. If the answer is more than one and nobody tested them apart, the evidence belongs to the formula, not to the plant on the label.